A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Glucagon-Like Peptide 1; Insulin; Insulin Glargine; Insulin, Globin Zinc; rGLP-1 protein

Criteria

Inclusion Criteria:

• type 2 diabetes

• BMI 20-45kg/m2 inclusive

Exclusion Criteria:

• females who are pregnant, lactating or within <6 weeks post-partum

• current symptomatic heart failure (NYHA Class III-IV)